Answers are grounded in this paper and cite their sources.
This editorial reflects on the role of sotatercept in promoting reverse remodeling of the right ventricle in pulmonary arterial hypertension, based on echo and hemodynamic data from the STELLAR trial.
Pulmonary arterial hypertension (PAH) is a severe progressive disease characterised by obliterative vascular remodelling and increased resistance in small and medium sized pulmonary arteries. Contributing factors to PAH pathogenesis include genetic mutations including those in bone morphogenetic protein receptor type 2 (BMPR2), perivascular inflammation, systemic immune dysregulation, and imbalanced pulmonary vascular cell proliferation versus apoptosis [1]. We reflect on the crucial role for a reverse remodelling approach supported by the echo and haemodynamic data from this post hoc analysis of STELLAR.
No takes yet. Share an insight, caveat, or question.
Price et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: